Mirion Technologies Appoints Dr. Sheila Rege, M.D. to Board of Directors, Replacing Mr. Christopher Warren
September 19 2022 - 8:00AM
Business Wire
Mirion Technologies, Inc. (“Mirion,” “we” or the “Company”)
(NYSE: MIR), a global provider of radiation detection, measurement,
analysis and monitoring solutions to the medical, nuclear, defense,
and research end markets, today announced that Dr. Sheila Rege,
M.D. has been appointed to the Board of Directors, replacing Mr.
Christopher Warren, who is stepping down.
Lawrence D. Kingsley, Chairman of Mirion’s Board of Directors
said, “I am pleased to welcome Sheila to Mirion’s Board of
Directors. She brings deep experience and a long track record of
accomplishment in nuclear medicine and radiation oncology to
Mirion’s Board. We are excited to have Sheila join us and believe
that her diverse skill set and voice will be invaluable as Mirion
aims to grow its Medical segment to at least 50% of total company
revenue over time.”
“It is a great honor to have been appointed to Mirion’s Board of
Directors,” said Dr. Rege. “I am a strong believer in Mirion’s
mission and feel that the Company has strong growth prospects,
especially within the Medical segment. I am excited to begin
working alongside my fellow Board members and the management team
to contribute to the Company’s future success.”
Dr. Rege is a board-certified radiation oncologist and the
Founder and Chief Executive Officer of Northwest Cancer Clinic, a
provider of radiation oncology and nuclear medicine services, which
opened in 2012. Dr. Rege joins Mirion’s Board of Directors with
over 30 years of experience in the field of nuclear medicine and
radiation oncology. From 2007 to 2019, Dr. Rege sat on the Board of
Directors of Physicians Insurance, serving as the Chair of the
Nominating Committee and a member of the Compensation, Executive
and CEO Succession Committees. Dr. Rege is the recipient of
numerous awards and accolades including the American Medical
Association Women Physician Section Inspiration Award in 2021, the
Private Company Boardroom 2022 “Directors to Watch”, The American
College of Radiation Oncology 2022 Sucha Asbell Mentorship Award,
and has been recognized as a “Top Oncologist” by the Consumer
Research Council of America in 2012. Dr. Rege received her B.A.
from the University of California, Berkeley, and her M.D. from the
University of California, Los Angeles.
“I would also like to thank Chris Warren for all of his
contributions to Mirion’s Board,” continued Mr. Kingsley. “Chris
and the Charterhouse team have been an incredibly supportive
partner, playing a key role in Mirion’s growth journey since their
initial investment in 2015. We wish Chris all the best in his
future endeavors.”
Chris Warren stated, “I leave Mirion’s Board with a great deal
of pride in the work we have been able to accomplish together.
Since Charterhouse first acquired Mirion in 2015, the Company has
undergone a strategic evolution through the expansion of its
Medical segment, while delivering strong growth. I exit the Board
at a point in Mirion’s history when the Company is experiencing
strong order and demand momentum, supported by healthy and robust
end markets. I believe the Company is in tremendous hands and am
excited to see what the team will accomplish in the years to
come.”
About Mirion Mirion Technologies is a leading provider of
detection, measurement, analysis and monitoring solutions to the
nuclear, defense, medical and research end markets. The
organization aims to harness its unrivaled knowledge of ionizing
radiation for the greater good of humanity. Headquartered in
Atlanta (GA – USA), Mirion employs around 2,800 people and operates
in 13 countries. For more information, and for the latest news and
content from Mirion, visit ir.mirion.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220919005186/en/
For investor inquiries: Jerry Estes ir@mirion.com
For media inquiries: Matthew Maddox
mmaddox@mirion.com
Mirion Technologies (NYSE:MIR)
Historical Stock Chart
From May 2024 to Jun 2024
Mirion Technologies (NYSE:MIR)
Historical Stock Chart
From Jun 2023 to Jun 2024